Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 33, 2009 - Issue sup1
227
Views
51
CrossRef citations to date
0
Altmetric
PROCEEDINGS OF THE 1ST PAN-MIDDLE EASTERN CONFERENCE ON HAEMOGLOBINOPATHIES DAMASCUS (SYRIA), 1–2 MAY, 2009 GUEST EDITORS: MICHAEL ANGASTINIOTIS AND ANDROULLA ELEFTHERIOUThe First Section: Prevention of Haemoglobin Disorders

Prevention of Hemoglobinopathies in Egypt

&
Pages S14-S20 | Published online: 13 Dec 2009
 

Abstract

The hemoglobin disorders are the most common clinically serious single gene disorders in the world. In Egypt, β-thalassemia is the most common type with a carrier rate varying from 5.3 to ≥9% and a gene frequency of 0.03. So, it was estimated that 1,000/1.5 million per year live births will suffer from thalassemia disease in Egypt (total live births 1,936,205 in 2006). β-Thalassemia creates a social and financial burden for the patients' family and the Egyptian government. The high frequency of β-thalassemia carriers with increasing rate of newly born cases is a pressing reason for the importance to develop prevention program for β-thalassemia in Egypt. Sickle-cell disease (SCD) is not frequent in Egypt except in the Oases where the carrier rate varies from 9 to 22%. Our objectives were to provide an in-depth analysis of the current status of hemoglobinopathies in Egypt and what we need for prevention of these diseases.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.